🔗 Share this article

A shadow economy for unapproved weight-loss drugs is being driven by social media fitness personalities and sellers on communication apps, according to recent findings.

Investigational Treatment Acquiring Popularity Online

The experimental drug, which is still in research studies, is being promoted by online personalities for its supposed fat-burning effects. Followers are encouraged to contact these accounts privately for supplier links, while also receiving promotional offers.

Thriving Trade on Social Networks

Additionally, a flourishing trade exists on Telegram, where groups with numerous of participants share “before and after” photos, administration instructions and claims of next-day UK delivery. Vendors promote the drug there before redirecting customers to other platforms for transactions.

Understanding The Experimental Drug

This medication is an experimental injection created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help individuals reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted digitally as the next Ozempic.

Healthcare Professionals Express Concerns

Nevertheless, physicians and chemists have cautions that the sale of what remains an unlicensed drug in the UK is worrisome and could result in users injecting products of unknown origin.

Some professionals said the demand for the experimental drug could be linked to the rising price of licensed weight loss treatments such as Mounjaro.

Regulatory Status and Enforcement

Selling retatrutide on social media or messaging apps is prohibited in the UK, as it is an unlicensed medication that cannot be promoted or distributed for personal consumption under the British medical regulations.

Some content creators try to sidestep the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and supply can still violate medicines, advertising, and customer laws, potentially leading to penalties, legal action or prison.

Platform Response and Material Removal

According to TikTok, the platform has removed violative content and banned associated hashtags and search suggestions. The company said it was dedicated to maintaining the platform secure and investing in enhancing enforcement strategies.

Online Trading Activities

Investigations also found groups with up to nine thousand participants selling retatrutide using Telegram's built-in search feature, which operates like a public directory. Typing “retatrutide” instantly brings up groups with numerous of members, filled with photos of slimming results, positive reviews and detailed instructions for mixing or administering at home.

Within moments of entering one community, a vendor shared WhatsApp details, where most transactions take place. The seller sent an instruction manual and promised delivery within 48 hours. When questioned whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. None inquired about body mass, medical conditions or past usage.

Item Information and Costs

Inside these groups, messages show black plastic parcels with Royal Mail labels, stating to contain new batches. One message read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, mixed at residence with sterile water, or pre-filled injectors typically sold at £160 for 20mg. When questioned how much time a injector should be used, sellers give contradictory answers ranging from a few weeks to “depends on your body”.

Platform Moderation and Security Actions

A representative for Telegram stated it actively monitored harmful content on its platform including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“People are injecting materials they can’t verify. Although the science behind this drug is valid, these digital versions may not contain what they advertise,” stated a pharmacy expert, the head of pharmacy at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the increase in interest to recent price rises for approved slimming medications such as Mounjaro. “With costs increasing, patients are using social media. But fake treatments are extremely risky. You cannot know what’s inside or whether the environment they were made in was sterile,” she explained.

Her staff has previously seen patients injured by self-injection from unconfirmed suppliers. “We recognize the disappointment, but buying from Telegram or communication platforms is gambling with your well-being,” said Wyllie. “These materials could be impure or improperly measured.”

Manufacturer Position

A spokesperson from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this time no one can market [it] for personal consumption,” they said, adding that any item “misleadingly claiming itself as a company investigational product not yet authorized … may expose users to possibly significant health risks”.